University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Yerem Yeghiazarians, M.D.

Interventional cardiologist

Dr. Yerem Yeghiazarians is co-director of the Adult Cardiac Catheterization Laboratory, director of the Peripheral Interventional Cardiology Program and director of the UCSF Translational Cardiac Stem Cell Program. He is an expert in managing patients with coronary artery disease, acute coronary syndromes, valvular heart disease, cardiomyopathies, patent foramen ovale and peripheral arterial diseases.

Yeghiazarians earned an undergraduate degree from Brandeis University and a medical degree from the Johns Hopkins School of Medicine. He trained in internal medicine at Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, where he was chief medical resident and an instructor in medicine. He also completed general and interventional adult cardiology training at Brigham and Women's Hospital. At UCSF, he is an associate professor of cardiology.

Clinics

Cardiovascular Care and Prevention Center at Mission Bay
535 Mission Bay Blvd. South
San Francisco, CA 94158
Phone: (415) 353-2873
Fax: (415) 353-2528

Hours: Monday to Friday
8 a.m. – 5 p.m.

Heart Valve Disease Clinic
535 Mission Bay Blvd. South
San Francisco, CA 94158
Phone: (415) 353-2873
Fax: (415) 353-2528

Hours: Monday through Friday, 8 a.m. – 5 p.m.

HHT Center of Excellence
2330 Post St., Suite 100
San Francisco, CA 94115
Phone: (415) 353-1300
Fax: (415) 353-8570

Hours: Monday to Friday,
8 a.m. – 4:30 p.m.

Conditions & Treatments

More about Yerem Yeghiazarians

Additional Languages

Armenian
French
Persian

Education

Johns Hopkins University School of Medicine 1995

Residencies

Brigham and Women's Hospital-Harvard Medical School, Internal Medicine 1998

Fellowships

Brigham and Women's Hospital-Harvard Medical School, Cardiology 2003

Selected Research and Publications

  1. Gupta V, Feng K, Cheruvu P, Boyer N, Yeghiazarians Y, Ports TA, Zimmet J, Shunk K, Boyle AJ. High Femoral Artery Bifurcation Predicts Contralateral High Bifurcation: Implications for Complex Percutaneous Cardiovascular Procedures Requiring Large Caliber and/or Dual Access. J Invasive Cardiol. 2014 Sep; 26(9):409-12.
  2. Boyer N, Gupta R, Schevchuck A, Hindnavis V, Maliske S, Sheldon M, Drachman D, Yeghiazarians Y. Coronary artery aneurysms in acute coronary syndrome: case series, review, and proposed management strategy. J Invasive Cardiol. 2014 Jun; 26(6):283-90.
  3. Yeghiazarians Y, Honbo N, Imhof I, Woods B, Aguilera V, Ye J, Boyle AJ, Karliner JS. IL-15: A Novel Prosurvival Signaling Pathway in Cardiomyocytes. J Cardiovasc Pharmacol. 2014 May; 63(5):406-11.
  4. Ye J, Yeghiazarians Y. Cardiac stem cell therapy: review of the native cardiac progenitor cells and future direction. J Cardiovasc Pharmacol. 2014 Feb; 63(2):85-94.
  5. Boyle AJ, Hwang J, Ye J, Shih H, Jun K, Zhang Y, Fang Q, Sievers R, Yeghiazarians Y, Lee RJ. The effects of aging on apoptosis following myocardial infarction. Cardiovasc Ther. 2013 Dec; 31(6):e102-10.
  6. Horn P, Amabile N, Angeli FS, Sansone R, Stegemann B, Kelm M, Springer ML, Yeghiazarians Y, Schroeter H, Heiss C. Dietary flavanol intervention lowers the levels of endothelial microparticles in coronary artery disease patients. Br J Nutr. 2014 Apr; 111(7):1245-52.
  7. Boyer N, Beyer A, Gupta V, Dehghani H, Hindnavis V, Shunk K, Zimmet J, Yeghiazarians Y, Ports T, Boyle A. The effects of intra-arterial vasodilators on radial artery size and spasm: implications for contemporary use of trans-radial access for coronary angiography and percutaneous coronary intervention. Cardiovasc Revasc Med. 2013 Nov-Dec; 14(6):321-4.
  8. Ameri K, Rajah AM, Nguyen V, Sanders TA, Jahangiri A, Delay M, Donne M, Choi HJ, Tormos KV, Yeghiazarians Y, Jeffrey SS, Rinaudo PF, Rowitch DH, Aghi M, Maltepe E. Nuclear localization of the mitochondrial factor HIGD1A during metabolic stress. PLoS One. 2013; 8(4):e62758.
  9. Beyer AT, Ng R, Singh A, Zimmet J, Shunk K, Yeghiazarians Y, Ports TA, Boyle AJ. Topical nitroglycerin and lidocaine to dilate the radial artery prior to transradial cardiac catheterization: a randomized, placebo-controlled, double-blind clinical trial: the PRE-DILATE Study. Int J Cardiol. 2013 Oct 3; 168(3):2575-8.
  10. Amabile N, Guignabert C, Montani D, Yeghiazarians Y, Boulanger CM, Humbert M. Cellular microparticles in the pathogenesis of pulmonary hypertension. Eur Respir J. 2013 Jul; 42(1):272-9.
  11. Ye J, Boyle AJ, Shih H, Sievers RE, Wang ZE, Gormley M, Yeghiazarians Y. CD45-positive cells are not an essential component in cardiosphere formation. Cell Tissue Res. 2013 Jan; 351(1):201-5.
  12. Majure DT, Hallaux M, Yeghiazarians Y, Boyle AJ. Topical nitroglycerin and lidocaine locally vasodilate the radial artery without affecting systemic blood pressure: a dose-finding phase I study. J Crit Care. 2012 Oct; 27(5):532.e9-13.
  13. Angeli FS, Zhang Y, Sievers R, Jun K, Yim S, Boyle A, Yeghiazarians Y. Injection of human bone marrow and mononuclear cell extract into infarcted mouse hearts results in functional improvement. Open Cardiovasc Med J. 2012; 6:38-43.
  14. Koskenvuo JW, Sievers RE, Zhang Y, Angeli FS, Lee B, Shih H, Ye J, Boyle AJ, Yeghiazarians Y. Fractionation of mouse bone-marrow cells limits functional efficacy in non-reperfused mouse model of acute myocardial infarction. Ann Med. 2012 Dec; 44(8):829-35.
  15. Ye J, Boyle A, Shih H, Sievers RE, Zhang Y, Prasad M, Su H, Zhou Y, Grossman W, Bernstein HS, Yeghiazarians Y. Sca-1+ cardiosphere-derived cells are enriched for Isl1-expressing cardiac precursors and improve cardiac function after myocardial injury. PLoS One. 2012; 7(1):e30329.
  16. Yeghiazarians Y, Gaur M, Zhang Y, Sievers RE, Ritner C, Prasad M, Boyle A, Bernstein HS. Myocardial improvement with human embryonic stem cell-derived cardiomyocytes enriched by p38MAPK inhibition. Cytotherapy. 2012 Feb; 14(2):223-31.
  17. Aschbacher K, Chen Q, Varga M, Haddad DJ, Yeghiazarians Y, Epel E, Wolkowitz OM, Springer ML. Higher fasting glucose levels are associated with reduced circulating angiogenic cell migratory capacity among healthy individuals. Am J Cardiovasc Dis. 2012; 2(1):12-9.
  18. Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation. 2011 Oct 25; 124(17):1838-47.
  19. Wang X, Takagawa J, Lam VC, Haddad DJ, Tobler DL, Mok PY, Zhang Y, Clifford BT, Pinnamaneni K, Saini SA, Su R, Bartel MJ, Sievers RE, Carbone L, Kogan S, Yeghiazarians Y, Hermiston M, Springer ML. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response. Sci Transl Med. 2011 Sep 14; 3(100):100ra90.
  20. Boyle AJ, Yeghiazarians Y, Shih H, Hwang J, Ye J, Sievers R, Zheng D, Palasubramaniam J, Palasubramaniam D, Karschimkus C, Whitbourn R, Jenkins A, Wilson AM. Myocardial production and release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man. J Transl Med. 2011; 9:150.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.